Pregabalin, a Ca 2+ channel α 2 δ-subunit antagonist with analgesic and antiepileptic activity, reduced neuronal loss and improved functional outcome in a mouse model of focal ischemic stroke. Pregabalin administration (5-10 mg/kg, i.p.) 30-90 min after transient middle cerebral artery occlusion/reperfusion reduced infarct volume, neuronal death in the ischemic penumbra and neurological deficits at 24 h post-stroke. Pregabalin significantly decreased the amount of Ca 2+ /calpain-mediated α-spectrin proteolysis in the cerebral cortex measured at 6 h post-stroke. Together with the extensive clinical experience with pregabalin for other neurological indications, our findings suggest the potential for a therapeutic benefit of pregabalin in stroke patients.
Introduction
Increasing the survival of neurons in the ischemic penumbra is a major goal for the development of drugs for treating stroke patients in the first few hours to days after the ischemic event (Hossmann, 2006; Tuttolomondo et al., 2009) . Cell membrane depolarization, excessive release of the excitatory neurotransmitter glutamate, and Ca 2+ influx through N-methyl-D-aspartate (NMDA) receptor channels and voltage-gated Ca 2+ channels endanger neurons in the ischemic penumbra (Choi, 1988; Barone et al., 1997) . Although NMDA receptor antagonists were effective in reducing brain damage in animal models of stroke, clinical trials in human stroke patients proved unsuccessful, in part because of severe side effects (Muir, 2006) . Voltage-gated Ca 2+ channels (VGCC) are multi-subunit integral membrane protein complexes that include a Ca 2+ -permeable α1 subunit (of which there are at least 10 encoded by separate genes) and modulatory γ, β and α2-δ subunits. Pregabalin (S-3-(aminomethyl)-5-methylhexanoic acid) is used to control neurogenic pain in various clinical conditions including fibromyalgia, diabetic neuropathy and complex regional pain syndrome (Lyseng-Williamson and Siddiqui, 2008) . Although pregabalin is a structural analogue of the neurotransmitter γ-aminobutyric acid, its pharmacological actions are mediated by binding to the α 2 -δ subunit of VGCC (Taylor et al., 2007 
Methods

Animals
Male C57BL/6 mice (Jackson Laboratories), 4-6 months of age and weighing 25-29 g at the time of surgery, were used for all experiments. The mice were group-housed and maintained on a 12 h light/12 h dark cycle, with ad libitum access to water and rodent chow. All procedures were in accordance with the NIH guidelines for the care and use of animals in research, and were performed with approval from the National Institute on Aging Animal Care and Use Committee.
Drug treatment
In an initial set of studies, pregabalin (S-[+]-3-isobutyl-γ-aminobutyric acid, N99.9% purity) or 0.5% carboxymethyl cellulose (CMC; vehicle) was administered intraperitoneally (i.p.; 10 mg/kg) a pretreatment (at 60 min before reperfusion, n = 7) and a post-treatment (just after, and 30 min after middle cerebral artery occlusion and 
